PA-ABEC
8.3.2022 15:39:06 CET | Business Wire | Press release
ABEC , a leading global provider of engineered solutions and services for biotech manufacturing, today announced it will provide customized, large-scale bioprocess equipment, including a 14,500 liter total volume stainless steel fermenter and an 8,000 liter media preparation system to EKF Life Sciences , a division of EKF Diagnostics Holdings plc, which manufactures diagnostics enzymes and contracted custom products for use in medical diagnostics, pharmaceutical and industry. The agreement provides EKF Life Sciences’ South Bend, Indiana facility with the bioprocess equipment which will significantly expand EKF’s production capacity of enzymes used in a variety of diagnostic and Life Science applications.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220308005235/en/
An industry leader in high-quality diagnostic materials, EKF is committed to the timely and cost-effective supply of critical products to the global life science and healthcare industries. ABEC has over 45 years of experience in large-scale fermenter design and complete in-house engineering and manufacturing capabilities. ABEC will provide engineering services for EKF’s new fermentation facility to ensure optimal process performance and seamless facility integration. The 14,500 liter fermenter will feature ABEC’s patented internal cooling panels, which will enable efficient sanitation, optimal heat removal and the highest possible fermenter productivity.
“EKF Life Sciences is dedicated to developing new products and capabilities that best serve the in vitro diagnostic market on a global scale. The partnership with ABEC is another important step in accelerating our organic growth strategy,” said Mike Salter, CEO of EKF Diagnostics Holdings plc. “Their innovative equipment and resources will enable us to quickly deliver our specific manufacturing requirements and we look forward to working with them as we continue to expand our biomanufacturing capabilities and capacity.”
“ABEC’s innovative technologies and complete turnkey solutions are unique in the industry,” said Scott Pickering, ABEC CEO and Chairman. “We look forward to continuing to support EKF’s expansion and growth.”
About ABEC
Since 1974, ABEC has been a global leader in delivering engineered process solutions and services for manufacturing in the biotech industry. A majority of the world's pharmaceutical and biotech companies are ABEC customers; with many of today's leading therapies manufactured by processes and equipment engineered, manufactured, installed and serviced by ABEC. ABEC's unique value is based on long experience, complete in-house capabilities, a custom, flexible approach, and long-term credibility. Whether adding capacity or improving existing facilities, ABEC's turn-key solutions and support services reduce overall cost and time to market while delivering maximum productivity. Visit: abec.com , email info@abec.com .
About EKF Life Sciences
EKF Life Sciences has been manufacturing enzymes and related biomolecules from bacterial fermentation for use in IVD since 1983. Since then, it has developed core competencies in technology transfer to commercialization, and the scale up of fermentation processes from bench top vessels to manufacturing large scale stable and reliable enzymes. These enzymes can be consistently produced in bulk scale for mass production of test kits.
With the continued development of microbial expression platforms and the expanding interest in medical and industrial applications for biologically produced intermediates and products, EKF Life Sciences serves as a critical link in the evolution of improved and environmentally sensitive manufacturing processes.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220308005235/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AHS Properties to Launch USD 1.3 Billion AHS Twin Towers, a Grade A Commercial Office Building on Sheikh Zayed Road27.10.2026 13:17:00 CET | Press release
AHS Properties is set to launch AHS Twin Towers, its new commercial development on Sheikh Zayed Road, following the AED 1.1 billion acquisition of Shangri-La Dubai. The property will undergo a major transformation into a Grade A commercial destination. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261027110920/en/ Abbas Sajwani, Founder and CEO of AHS Properties (Photo: AETOSWire) Positioned on one of Dubai’s most prominent commercial corridors, AHS Twin Towers will introduce a new architectural identity for the property. The project has been designed by Gensler, an internationally recognised architecture and design firm, with interiors by AHS Atelier, the company’s in-house design studio, bringing a bespoke approach to materiality, detailing and craftsmanship throughout the development. AHS Twin Towers will comprise ground floor plus 50. The development will offer flexible Grade A office environments supported by an integr
JERA Signs a Binding Heads of Agreement with AM Green for Long-Term Supply of Green Ammonia for Maritime Decarbonization27.10.2026 13:11:00 CET | Press release
JERA Co., Inc. (JERA) and AM Green Ammonia (India) Private Limited (AM Green) today jointly announced that it has entered into a Binding Heads of Agreement ("HoA") with AM Green regarding the long-term supply of green ammonia produced in India. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261027189014/en/ JERA and AM Green have agreed upon supply of approximately 70,000 tonnes of green ammonia annually over five years, with potential extension of term for additional supply. The green ammonia is intended to be supplied through receiving, storage and distribution facilities being developed adjacent to JERA's Hekinan Thermal Power Station in Aichi Prefecture, Japan. Green ammonia would primarily be supplied to a business venture jointly to be established by Kawasaki Kisen Kaisha, Ltd. and Nippon Yusen Kabushiki Kaisha, which plans to utilize an ammonia bunkering vessel to supply fuel to ammonia-fueled car carriers. This marks
Pythia Labs Launches with AI-Designed Antibodies for Hard-to-Drug Targets27.10.2026 13:00:00 CET | Press release
Biotech startup demonstrates rapid AI design of full-length human antibodies that inhibit or activate GPCRs, with key properties required for therapeutic development Pythia Labs, a biotechnology company building frontier AI models for therapeutic discovery, today announced its launch alongside a preprint in bioRxiv introducing Pythia-1, the all-atom generative model at the core of its antibody design platform. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261027891477/en/ Pythia's AI technology platform can design antibodies against traditionally challenging targets such as multi-pass membrane proteins. Pythia’s technology is built to create antibodies against targets that have challenged conventional discovery, including multi-pass membrane proteins such as G protein-coupled receptors (GPCRs). Generating antibodies that activate these receptors has been a longstanding goal in antibody discovery. Pythia-1 reasons jointly ov
Robbyant’s Inaugural Embodied AI Challenge Draws Over 1,800 Teams Ahead of Real-Robot Final in Shanghai27.10.2026 12:00:00 CET | Press release
Qualifier submissions for the inaugural Robbyant Embodied AI Challenge officially closed on October 27, marking the end of the competition’s online preliminary round. Organized by Robbyant, an embodied AI company within Ant Group, the challenge was launched in September at the 2026 Inclusion Conference on the Bund in partnership with ModelScope and Alibaba Cloud Tianchi. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261027768483/en/ The competition is based on the open-source LingBot-VLA 2.0 embodied foundation model and is designed for developers working on embodied AI algorithms. Participants are evaluated on model training and fine-tuning, simulation-based generalization, and adaptation to real robots. The challenge is open to enterprises, universities, individual developers and technology enthusiasts worldwide. More than 1,800 teams and thousands of developers from 13 countries have registered for the challenge. Partici
Compass Pathways to Announce Third Quarter 2026 Financial Results on November 3, 202627.10.2026 11:30:00 CET | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that it will release financial results for the third quarter ended September 30, 2026, and provide an update on recent developments, on November 3, 2026. Compass management will host a conference call at 8:00 am ET (1:00 pm UK) on November 3, 2026. A live webcast of the call will be available at the following link: https://lifescievents.com/event/csy40je/. The webcast will be archived for 30 days. About Compass Pathways We believe mental health patients deserve the possibility of a better future. Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care. Our initial focus is developing COMP360 psilocybin, a proprietary, investigational, synthetic psilocybin treatment under evaluation for treatment-resistant depression (TRD) and post-traumati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
